Literature DB >> 28365160

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer.

Michael T Schweizer1, Emmanuel S Antonarakis2, Samuel R Denmeade3.   

Abstract

Bipolar androgen therapy (BAT) is a paradoxical treatment for castrate-resistant prostate cancer whereby testosterone levels are rapidly alternated between supraphysiologic and near-castrate concentrations. Initial studies demonstrated that BAT is safe and produces clinical responses. A trial comparing enzalutamide against BAT is ongoing.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28365160      PMCID： PMC5872811          DOI： 10.1016/j.eururo.2017.03.022

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  23 in total

1.  Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1.

Authors:  Changmeng Cai; Housheng Hansen He; Sen Chen; Ilsa Coleman; Hongyun Wang; Zi Fang; Shaoyong Chen; Peter S Nelson; X Shirley Liu; Myles Brown; Steven P Balk
Journal:  Cancer Cell       Date:  2011-10-18       Impact factor: 31.743

2.  Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cells.

Authors:  Ivan V Litvinov; Donald J Vander Griend; Lizamma Antony; Susan Dalrymple; Angelo M De Marzo; Charles G Drake; John T Isaacs
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

3.  Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer.

Authors:  John T Isaacs; Jason M D'Antonio; Shuangling Chen; Lizamma Antony; Susan P Dalrymple; Georges H Ndikuyeze; Jun Luo; Samuel R Denmeade
Journal:  Prostate       Date:  2012-03-06       Impact factor: 4.104

4.  Bipolar androgen therapy: the rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer.

Authors:  Samuel R Denmeade; John T Isaacs
Journal:  Prostate       Date:  2010-10-01       Impact factor: 4.104

5.  Mechanism of androgen action on cell proliferation: AS3 protein as a mediator of proliferative arrest in the rat prostate.

Authors:  Maricel V Maffini; Peter Geck; Charles E Powell; Carlos Sonnenschein; Ana M Soto
Journal:  Endocrinology       Date:  2002-07       Impact factor: 4.736

6.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

7.  Testosterone replacement in prostate cancer survivors with hypogonadal symptoms.

Authors:  Robert L Leibowitz; Tanya B Dorff; Steven Tucker; James Symanowski; Nicholas J Vogelzang
Journal:  BJU Int       Date:  2009-11-11       Impact factor: 5.588

8.  Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements.

Authors:  Michael C Haffner; Martin J Aryee; Antoun Toubaji; David M Esopi; Roula Albadine; Bora Gurel; William B Isaacs; G Steven Bova; Wennuan Liu; Jianfeng Xu; Alan K Meeker; George Netto; Angelo M De Marzo; William G Nelson; Srinivasan Yegnasubramanian
Journal:  Nat Genet       Date:  2010-07-04       Impact factor: 38.330

Review 9.  Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

Authors:  Chih-Pin Chuu; John M Kokontis; Richard A Hiipakka; Junichi Fukuchi; Hui-Ping Lin; Ching-Yu Lin; Chiech Huo; Liang-Cheng Su
Journal:  J Biomed Sci       Date:  2011-08-23       Impact factor: 8.410

10.  Androgen suppresses the proliferation of androgen receptor-positive castration-resistant prostate cancer cells via inhibition of Cdk2, CyclinA, and Skp2.

Authors:  John M Kokontis; Hui-Ping Lin; Shih Sheng Jiang; Ching-Yu Lin; Junichi Fukuchi; Richard A Hiipakka; Chi-Jung Chung; Tzu-Min Chan; Shutsung Liao; Chung-Ho Chang; Chih-Pin Chuu
Journal:  PLoS One       Date:  2014-10-01       Impact factor: 3.240
View more
  7 in total

Review 1.  Role of androgen receptor splice variants, their clinical relevance and treatment options.

Authors:  S Wach; H Taubert; M Cronauer
Journal:  World J Urol       Date:  2019-01-19       Impact factor: 4.226

Review 2.  [Splice variant AR-V7 : Is it time for its routine use as a predictive marker in prostate cancer?]

Authors:  I Tsaur; C Becker; P Thelen; F C Roos
Journal:  Urologe A       Date:  2017-09       Impact factor: 0.639

Review 3.  Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Authors:  Andrea K Miyahira; Adam Sharp; Leigh Ellis; Jennifer Jones; Salma Kaochar; H Benjamin Larman; David A Quigley; Huihui Ye; Jonathan W Simons; Kenneth J Pienta; Howard R Soule
Journal:  Prostate       Date:  2019-12-11       Impact factor: 4.104

4.  Androgenic modulation of AR-Vs.

Authors:  Ana Caroline Hillebrand; Lolita Schneider Pizzolato; Gisele Branchini; Ilma Simoni Brum
Journal:  Endocrine       Date:  2018-07-19       Impact factor: 3.633

5.  Response to supraphysiological testosterone is predicted by a distinct androgen receptor cistrome.

Authors:  Xintao Qiu; Lisha G Brown; Jennifer L Conner; Holly M Nguyen; Nadia Boufaied; Sarah Abou Alaiwi; Ji-Heui Seo; Talal El Zarif; Connor Bell; Edward O'Connor; Brian Hanratty; Mark Pomerantz; Matthew L Freedman; Myles Brown; Michael C Haffner; Peter S Nelson; Felix Y Feng; David P Labbé; Henry W Long; Eva Corey
Journal:  JCI Insight       Date:  2022-05-23

6.  Androgen Receptor Regulates CD44 Expression in Bladder Cancer.

Authors:  Joseph L Sottnik; Lauren Vanderlinden; Molishree Joshi; Ana Chauca-Diaz; Charles Owens; Donna E Hansel; Colin Sempeck; Debashis Ghosh; Dan Theodorescu
Journal:  Cancer Res       Date:  2021-03-09       Impact factor: 13.312

7.  Differential modulation of the androgen receptor for prostate cancer therapy depends on the DNA response element.

Authors:  Steven Kregel; Pia Bagamasbad; Shihan He; Elizabeth LaPensee; Yemi Raji; Michele Brogley; Arul Chinnaiyan; Marcin Cieslik; Diane M Robins
Journal:  Nucleic Acids Res       Date:  2020-05-21       Impact factor: 16.971
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.